Verrica reports 13,434 YCANTH dispensed applicator units in Q2

Verrica Pharmaceuticals (VRCA) experienced strong demand for YCANTH in Q2, with 13,434 dispensed applicator units during the quarter. These dispensed applicator units represent accelerating sequential growth of 32.8% over 1Q25, which was nearly double the previous sequential growth rate of 16.7% seen for 1Q25 over 4Q24. “We’re tremendously pleased and proud of our accelerating growth in the second quarter,” said Jayson Rieger, CEO. “The substantial growth for YCANTH dispensed applicator units in the second quarter proves that our more focused commercial strategy is driving significant product demand, with a growing number of both dermatology and pediatric physician practices now prescribing YCANTH. Our second quarter growth in dispensed applicator units also shows that our patient access strategy, strong reimbursement, and extensive distribution network are enabling a growing number of healthcare providers to conveniently and reliably access YCANTH for their patients.This increase in quarterly growth reflects the dedication of our team to daily execution on our strategy. Accelerating dispensed applicator unit growth, coupled with the recently announced amendments to our Credit Agreement with OrbiMed and our Collaboration and License Agreement with our Japanese development partner, Torii Pharmaceutical, provide tangible evidence of the progress we have made since last year. The flexibility provided by OrbiMed and the non-dilutive funding provided by Torii alongside our sales growth are the key pillars supporting our business. In addition, we are looking forward to providing an update on our development strategy for VP-315, our product candidate for basal cell carcinoma. In short, we are tremendously excited for the patients we serve and for what the future holds for Verrica.”